The cure for this new threat may rest with Cidara Therapeutics’ new antifungal drug, rezafungin. It currently is completing two Phase III trials. One treats candidemia and invasive candidiasis. On the other, rezafungin is used as a prophylactic for the prevention of fungal infections in a high-risk hematology setting. It shows efficacy against Candida spp., Aspergillus spp., Pneumocystis spp. and dermatophytes, can be administered safely at high doses, and it can clear the body of infection quickly.